Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries

MerckMerck, a leading science and technology ­company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.

"We have a long tradition of responsibility, it’s more than just lip service. That's why we want to share the great joy of our anniversary not only with our employees, but also with our local communities," said Walter Galinat, member of the Executive Board of Merck and responsible for the 350th anniversary celebrations. "We take on responsibility for society all over the world. Many of our employees and subsidiaries are involved in this effort, for instance through donations, collaborations with reliable partners and voluntary initiatives," he added.

The activities planned to take place throughout 2018 will focus on health as well as on education and culture. Here, Merck will leverage its 350 years of experience and curiosity, as well as its knowledge and expertise in the areas of health, science and technology. In addition to these efforts, the company also supports a wide array of charitable and environmental initiatives in the communities near its sites and provides disaster relief. The aim is to address challenges facing society, from fighting serious diseases and protecting natural resources to promoting aspiring young scientists.

The projects in the focus area of health are centered around developing local healthcare infrastructure, providing vocational and advanced training to medical staff and raising awareness of health issues. Founded in 2017, for instance, the Merck Foundation supports initiatives to improve the treatment of cancer patients in Africa. And in Guatemala, Merck is working with an organization that provides free healthcare to underprivileged communities and helps people with disabilities.

Within the focus area of education, particular emphasis is placed on sparking young people's interest in science. A prime example is the SPARK volunteer program, under which employees conduct scientific experiments with school children in an effort to arouse their curiosity. A large number of activities are also taking place in Darmstadt, where the company is headquartered. These include an exciting experiment afternoon for school students to mark the tenth anniversary of the Junior Laboratory at the Technical University of Darmstadt. In Indonesia, Merck is supporting the charitable organization Nara Kreatif, with which it is collaborating on environmental and educational projects. These include a school for 300 children in need, at which Merck employees are also volunteering.

Within the focus area of culture, Merck is often engaged in projects that transcend cultural borders, such as a literature initiative in Korea that encourages exchange between Germany and several Asian countries.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...